Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.
Pharmacogenomic testing for neuropsychiatric drugs: current status of drug labeling, guidelines for using genetic information, and test options.
复制标题
DOI:
10.1002/phar.1398
复制
发表时间:
2014-02
期刊:
影响因子:
4.1
通讯作者:
Bishop, Jeffrey R.
中科院分区:
文献类型:
--
作者:
Drozda, Katarzyna;Mueller, Daniel J.;Bishop, Jeffrey R.
关键词:
Advancements in pharmacogenomics have introduced an increasing number of opportunities to bring personalized medicine into clinical practice. Understanding how and when to use this technology to help guide pharmacotherapy used to treat neuropsychiatric conditions remains a challenge for many clinicians. Currently, guidelines exist to assist clinicians in the use of genetic information for drug selection and/or dosing for the tricyclic antidepressants, carbamazepine, and phenytoin. Additional language in the product labeling suggests that genetic information may also be useful for assessing the starting and target doses, as well as drug interaction potential, for a number of other medications used to treat psychiatric and neurological conditions. In this review, we outline the current status of pharmacogenomic testing for neuropsychiatric drugs as it pertains to information contained in drug labeling, consensus guidelines, and test panels, as well as considerations related to obtaining tests for patients.
登录
查看更多内容
影响因子:
6.7
作者:
Hicks, J. K.;Swen, J. J.;Stingl, J. C.
通讯作者:
Stingl, J. C.
影响因子:
14.9
作者:
Gonzalez-Galarza FF;Christmas S;Middleton D;Jones AR
通讯作者:
Jones AR
影响因子:
3.4
作者:
De Leon, J;Armstrong, SC;Cozza, KL
通讯作者:
Cozza, KL
影响因子:
--
作者:
Hresko A;Haga SB
通讯作者:
Haga SB
影响因子:
8.8
作者:
Berg, Alfred O.;Piper, Margaret;Teutsch, Steven
通讯作者:
Teutsch, Steven